Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles

References

• Li J, Wang Y, Zhu Y, Oupický D. Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. J Control Release 2013;172:589–600
   PubMed Web of Science ®Google Scholar
• Ewesuedo RB, Ratain MJ. Principles of cancer chemotherapy. In: Vokes E, Golomb H, eds. Oncologic therapeutics. New York: Springer; 2003:19–66
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930–42
   PubMed Web of Science ®Google Scholar
• Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012;18:5585–94
   PubMed Web of Science ®Google Scholar
• Ebermann R, Alth G, Kreitner M, Kubin A. Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. J Photochem Photobiol B 1996;36:95–7
   PubMed Web of Science ®Google Scholar
• Nguyen NP, Bishop M, Borok TJ, et al. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer Res 2010;30:953–61
   PubMed Web of Science ®Google Scholar
• Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973–85
   PubMed Web of Science ®Google Scholar
• Su WP, Cheng FY, Shieh DB, et al. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 2012;7:4269–83
   PubMed Web of Science ®Google Scholar
• Katas H, Abdul Ghafoor Raja M, Ee LC. Comparative characterization and cytotoxicity study of TAT-peptide as potential vectors for siRNA and Dicer-substrate siRNA. Drug Dev Ind Pharm 2014;40: 1443–50
   PubMed Web of Science ®Google Scholar
• Shu Y, Pi F, Sharma A, et al. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev 2014;66:74–89
   PubMed Web of Science ®Google Scholar
• Kawakami S, Hashida. M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007;22:142–51
   PubMed Web of Science ®Google Scholar
• Maurer N, Wong KF, Stark H, et al. Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J 2001;80:2310–26
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C, Martin F, et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29–36
   PubMed Web of Science ®Google Scholar
• Liu C, Liu F, Feng L, et al. The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 2013;34:2547–64
   PubMed Web of Science ®Google Scholar
• Zhang JL, Wang B, Shen Y, et al. Selection of specific siRNA inhibiting the expression of HIF-1. Phar Biotechnol 2014;21:115–17
   Google Scholar
• Van De Putte M, Roskams T, Bormans G, et al. The impact of aggregation on the biodistribution of hypericin. Int J Oncol 2006;28:655–60
   PubMed Web of Science ®Google Scholar
• Blank M, Lavie G, Mandel M, et al. Antimetastatic activity of the photodynamic agent hypericin in the dark. Int J Cancer 2004;111:596–603
   PubMed Web of Science ®Google Scholar
• Lin CW. Photodynamic therapy of malignant tumors-recent developments. Cancer Cells 1991;3:437–44
   PubMed Web of Science ®Google Scholar
• Huygens A, Kamuhabwa AR, Roskams T, et al. Permeation of hypericin in spheroids composed of different grade transitional cell carcinoma cell lines and normal human urothelial cells. J Urol 2005;174:69–72
   PubMed Web of Science ®Google Scholar
• Vandenbogaerde AL, Cuveele JF, Proot P, et al. Differential cytotoxic effects induced after photosensitization by hypericin. J Photochem Photobiol B 1997;38:136–42
   PubMed Web of Science ®Google Scholar
• Zeisser-Labouebe M, Lange N, Gurny R, Delie F. Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int J Pharm 2006;326:174–81
   PubMed Web of Science ®Google Scholar
• Emami J, Rezazadeh M, Rostami M, et al. Co-delivery of paclitaxel and α-tocopherol succinate by novel chitosan-based polymeric micelles for improving micellar stability and efficacious combination therapy. Drug Dev Ind Pharm 2015;41:1137–47
   PubMed Web of Science ®Google Scholar
• Cai S, Xie Y, Bagby TR, et al. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. J Surg Res 2008;147:247–52
   PubMed Web of Science ®Google Scholar
• Cho HJ, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials 2011;32:7181–90
   PubMed Web of Science ®Google Scholar
• Navarro G, Sawant RR, Essex S, et al. Phospholipid–polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res 2008;1:25–33
   Web of Science ®Google Scholar
• Jiang HL, Kwon JT, Kim YK, et al. Galactosylated chitosan-graft-polyethylenimine as a gene carrier for hepatocyte targeting. Gene Ther 2005;14:1389–98
   Web of Science ®Google Scholar
• Nam HY, Nam K, Hahn HJ, et al. Biodegradable PAMAM ester for enhanced transfection efficiency with low cytotoxicity. Biomaterials 2009;30:665–73
   PubMed Web of Science ®Google Scholar
• Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34 + stem/progenitor cells to bone marrow. Blood 2004;103:2981–9
   PubMed Web of Science ®Google Scholar
• Kim TH, Nah JW, Cho MH, et al. Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J Nanosci Nanotechnol 2006;6:2796–803
   PubMed Web of Science ®Google Scholar
• Teicher BA. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist Update 2000;3:67–73
   PubMed Web of Science ®Google Scholar
• Hajipour MJ, Fromm KM, Ashkarran AA, et al. Antibacterial properties of nanoparticles. Trends Biotechnol 2012;30:499–511
   PubMed Web of Science ®Google Scholar
• Shaw JM, Shaw KV, Yanovich S, et al. Delivery of lipophilic drugs using lipoproteins. Ann N Y Acad Sci 1987;507:252–71
   PubMed Web of Science ®Google Scholar
• Kiesslich T, Krammer B, Plaetzer. K. Cellular mechanisms and prospective applications of hypericin in photodynamic therapy. Curr Med Chem 2006;13:2189–204
   PubMed Web of Science ®Google Scholar
• Chung PS, Saxton RE, Paiva MB, et al. Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy. Laryngoscope 1994;104:1471–6
   Google Scholar
• Sanovic R, Verwanger T, Hartl A, Krammer B. Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma. Photodiagnosis Photodyn Ther 2011;8:291–6
   PubMed Web of Science ®Google Scholar